Review article · 2026 · Open access
Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer
CA A Cancer Journal for Clinicians, 76(1), e70055 · Published 1 January 2026 · DOI 10.3322/caac.70055
In brief
“Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer” is a 2026 review article by Akshara Singareeka Raghavendra and 5 co-authors, published in CA A Cancer Journal for Clinicians. OpenAlex counts 23 citations as of 17 November 2026, which puts it in the top 1% of works published in 2026 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at CA A Cancer Journal for Clinicians.
- Citations
- 23
- Most cited in
- 2026 (23)
- Field-weighted impact
- 12.68
- References
- 190
- Authors
- 6
Abstract
The hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer subtype accounts for most early and metastatic breast cancer (MBC) cases. HR-positive/HER2-negative MBC is characterized by a relatively prolonged, although variable, disease course and substantial intertumoral and intratumoral heterogeneity. Although endocrine-based therapies remain the cornerstone of treatment, nearly all patients eventually develop resistance, which is increasingly addressed with biologically targeted agents and newer-generation cytotoxic drugs. This review summarizes the current understanding of HR-positive/HER2-negative MBC biology, highlighting mechanisms of intrinsic and acquired resistance, including driver genomic alterations that, along with clinical factors, help guide therapeutic choices and sequencing. The authors specify and discuss how genomic and transcriptomic profiling inform treatment selection and how side effects and overall patient experience are considered in decision making. Advances in targeted therapies, such as CDK4/6 (cyclin-dependent kinase 4/6), PI3K (phosphatidylinositol 3-kinase), and AKT (protein kinase B) inhibitors, and next-generation estrogen receptor degraders are reviewed along with the expanding role of antibody-drug conjugates and biomarker-guided tumor-agnostic biologic therapies. The authors also explore evolving biologic concepts, including the impact of the tumor microenvironment on resistance and disease progression, and consider the distinct clinical behavior of invasive lobular carcinoma and current approaches. Emerging data from contemporary clinical trials promise to refine clinical and biomarker-driven algorithms and improve outcomes for patients with HR-positive/HER2-negative MBC. Ongoing multi-omic research and adaptive clinical strategies will be essential to further the application of precision oncology in this most common subtype of MBC. Importantly, patient-reported outcomes, shared decision making, and real-world evidence are increasingly useful in formulating comprehensive care plans, guidelines, and policy. The modern treatment landscape features a personalized approach that integrates clinical features, biomarkers, and patient preferences across the disease continuum.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Raghavendra, A. S., Damodaran, S., Barcenas, C. H., Fuqua, S. A., Layman, R. M., & Tripathy, D. (2026). Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer. CA A Cancer Journal for Clinicians, 76(1), e70055. https://doi.org/10.3322/caac.70055
MLA 9
Raghavendra, Akshara Singareeka, et al. “Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer.” CA A Cancer Journal for Clinicians, vol. 76, no. 1, 2026, p. e70055. https://doi.org/10.3322/caac.70055.
Chicago
Raghavendra, Akshara Singareeka, Senthil Damodaran, Carlos Hernando Barcenas, Suzanne A.W. Fuqua, Rachel M. Layman, and Debu Tripathy. 2026. “Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer.” CA A Cancer Journal for Clinicians 76 (1): e70055. https://doi.org/10.3322/caac.70055.
Harvard
Raghavendra, A. S. et al. (2026) ‘Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer’, CA A Cancer Journal for Clinicians, 76(1), p. e70055. doi:10.3322/caac.70055.
IEEE
A. S. Raghavendra, S. Damodaran, C. H. Barcenas, S. A. Fuqua, R. M. Layman, and D. Tripathy, “Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer,” CA A Cancer Journal for Clinicians, vol. 76, no. 1, p. e70055, 2026, doi: 10.3322/caac.70055.
BibTeX
@article{raghavendra2026personalizing,
title = {{Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer}},
author = {Raghavendra, Akshara Singareeka and Damodaran, Senthil and Barcenas, Carlos Hernando and Fuqua, Suzanne A.W. and Layman, Rachel M. and Tripathy, Debu},
journal = {CA A Cancer Journal for Clinicians},
year = {2026},
volume = {76},
number = {1},
pages = {e70055},
doi = {10.3322/caac.70055},
url = {https://doi.org/10.3322/caac.70055}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- hormone receptor-positive HER2-negative breast cancer
- metastatic breast cancer
- endocrine therapy resistance
- CDK4/6 inhibitors
- PI3K/AKT inhibitors
- antibody-drug conjugates
- tumor-agnostic therapy
- tumor microenvironment
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Raghavendra, A. S., Damodaran, S., Barcenas, C. H., Fuqua, S. A., Layman, R. M., & Tripathy, D. (2026). Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer. CA A Cancer Journal for Clinicians, 76(1), e70055. https://doi.org/10.3322/caac.70055
How many times has this paper been cited?
23 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at CA A Cancer Journal for Clinicians: sign in and open the PDF from this page.
Who wrote this paper?
Akshara Singareeka Raghavendra, Senthil Damodaran, Carlos Hernando Barcenas, Suzanne A.W. Fuqua, Rachel M. Layman, Debu Tripathy.
What is the DOI of this paper?
10.3322/caac.70055, permanently at https://doi.org/10.3322/caac.70055. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.